[Research advances on baicalin and baicalein as potential therapeutic agents for fibrotic disease].

Tissue and organ fibrosis is the major cause for disability and death related to a variety of diseases worldwide. As specific therapies to halt, or even to reverse the existing tissue fibrosis are not yet available, it is of great significance to find new anti-fibrosis therapeutic agents. Tissue and organ fibrosis is a nonphysiological scarring process, associated with excessive deposition of extracellular matrix, and leads to impairment of organ function. Fibrotic lesions of all organs show similar histological abnormalities. In recent years, plenty of studies showed that Baicalin and baicalein had anti-fibrosis effects in different tissues or organs. In this paper, the effects and mechanisms of baicalin and baicalein on different organ fibrosis were reviewed. Baicalin and its aglycone baicalein had similarity in structural and pharmacological characteristics, with broad biotransformation effect within the body. The research suggested that baicalin and baicalein can suppress different tissue and organ fibrosis occurrence and development via various mechanisms, including down-regulating expression of promote-fibrosis cytokines, inhibiting pro-fibrogenic signaling pathways, anti-inflammatory and anti-oxidant effects. Though baicalin and baicalein are promising anti-fibrosis agents, there is still a long way to go before being approved as specific anti-fibrotic drugs.